All relevant data are within the paper and its Supporting Information files.

Introduction {#sec004}
============

Scrub typhus is a febrile illness caused by the obligate intracellular bacterium, *Orientia tsutsugamushi*. It is transmitted by the bite of infected larvae of a number of trombiculid mite species known to be prevalent in Asia, the Pacific Rim islands, pockets in the north of Australia, and some areas of Chile \[[@pntd.0006330.ref001]--[@pntd.0006330.ref004]\]. In 2010, a novel species from the same genus, *Orientia chuto* sp. nov., was identified in an acutely febrile patient infected in Dubai \[[@pntd.0006330.ref005]\]. Scrub typhus responds to certain antibiotics (i.e. doxycycline, tetracycline, azithromycin, chloramphenicol), but if left untreated, the mortality rate may reach 70% \[[@pntd.0006330.ref006]\]. One estimate, based on scant data, is that there are one billion people at risk of this disease; with one million clinical cases annually in Southeast Asia alone \[[@pntd.0006330.ref001]\]. Although the exact prevalence of scrub typhus is not available, several studies showed that the disease burden in rural Asia is high--causing in some areas over 20.0% of febrile illness admitted to hospital \[[@pntd.0006330.ref007],[@pntd.0006330.ref008]\].

Infected patients usually present with acute fever; lymphadenopathy (regional or generalised) and sensorineural hearing loss may occur, neither of which is sensitive or specific enough for establishing diagnosis \[[@pntd.0006330.ref001]\]. With few distinguishing clinical characteristics, scrub typhus is difficult to differentiate from other tropical febrile illnesses, such as dengue, typhoid fever, leptospirosis, and murine typhus \[[@pntd.0006330.ref001],[@pntd.0006330.ref009]\]. The presence of the pathognomonic eschar, the painless black crust at the site of mite inoculation, can help in establishing clinical diagnosis due to its high specificity (98.9%), however, its presence in patients varies widely (7.0%-97.0%) \[[@pntd.0006330.ref001],[@pntd.0006330.ref010]--[@pntd.0006330.ref012]\].

Therefore, the role of laboratory tests in establishing diagnosis in scrub typhus cases is very important. Laboratory tests for scrub typhus often have limited diagnostic accuracy and are generally in limited supply in resource-limited or outpatient settings \[[@pntd.0006330.ref009]\]. Failure in diagnosing scrub typhus may result in prolonged illness, complications including pneumonitis, acute respiratory distress syndrome, renal failure, meningoencephalitis, and unnecessary treatment with inappropriate antibiotics \[[@pntd.0006330.ref001],[@pntd.0006330.ref009],[@pntd.0006330.ref013]\].

Serology remains the mainstay of diagnosis. The immunofluorescent assay (IFA) and immunoperoxidase test (IIP) are considered imperfect gold standards, in view of their limitations which include high expense, requirement for substantial training to perform, inter-operator variability in result interpretation, and the often-retrospective nature of diagnosis that does not help in directing treatment \[[@pntd.0006330.ref001],[@pntd.0006330.ref009],[@pntd.0006330.ref012],[@pntd.0006330.ref014],[@pntd.0006330.ref015]\]. Another antibody detection method, the enzyme-linked immunosorbent assay (ELISA) has been developed and shown to have both sensitivity and specificity of greater than 90.0%; however this is highly dependent on endemicity and the application of a previously investigated and geographically-based cut-off \[[@pntd.0006330.ref001],[@pntd.0006330.ref016]\]. Besides antibody-based diagnostics, molecular detection methods, including using the polymerase chain reaction (PCR) to detect various genes targets (e.g. 47 kDa, 56 kDa, *groEL*, 16S rRNA genes) have also been developed, however they have limitations in terms of diagnostic sensitivity due to the limited period of rickettsaemia \[[@pntd.0006330.ref001],[@pntd.0006330.ref009],[@pntd.0006330.ref012],[@pntd.0006330.ref014]\]. PCR is still deemed impractical in resource-limited endemic areas because it requires considerable training and expense \[[@pntd.0006330.ref001],[@pntd.0006330.ref009],[@pntd.0006330.ref012],[@pntd.0006330.ref014]\]. The bacteria can be isolated through *in vitro* and *in vivo* cultivation methods, such as cell culture and mouse inoculation, respectively \[[@pntd.0006330.ref001],[@pntd.0006330.ref009]\]. These methods need considerable training, biosafety level 3 (BSL 3) laboratory containment facilities for large-scale propagation, and usually take several weeks which contributed to the retrospective nature of the diagnosis \[[@pntd.0006330.ref001],[@pntd.0006330.ref009]\].

Therefore, there is clearly a need for affordable point-of-care testing (POCT) for scrub typhus diagnosis in endemic settings with resource constraints. There are varied definitions of POCT, but fundamentally POCT should provide quick results to inform patient management and be convenient enough to be performed close to the patient (i.e. not in a central laboratory) \[[@pntd.0006330.ref017],[@pntd.0006330.ref018]\].

Immunochromatographic tests (ICTs), dot-blot, and loop-mediated isothermal amplification (LAMP) assays all have the principal qualities of POCT. ICTs and dot-blot tests have the same inherent problems of IFA as serology-based tests (e.g. the retrospective nature of diagnosis in cases where diagnosis relies on a convalescent sample, delicate cut-off setting), while offering more simplicity and speed \[[@pntd.0006330.ref001],[@pntd.0006330.ref009]\]. LAMP is an alternative technique which involves amplification and detection of bacterial DNA. Similar in principle to conventional PCR assays, LAMP assay does not require intricate DNA extraction, a thermocycler, or special equipment to read the result \[[@pntd.0006330.ref009],[@pntd.0006330.ref019],[@pntd.0006330.ref020]\].

This study aims to summarise the existing evidence on the accuracy of scrub typhus POCTs to inform clinical practitioners of their diagnostic value when providing care in resource-limited settings where scrub typhus is endemic.

Methods {#sec005}
=======

Eligibility criteria {#sec006}
--------------------

This review included articles on POCTs that would be feasible in primary health care provider or outpatient settings. Only articles published in English were included. To ensure feasibility in resource-limited settings, studies evaluating methods which were inherently more complicated, requiring relatively high levels of expertise and/or specialised equipment were excluded. Articles on POCTs not performed on human samples were excluded. Studies on the Weil-Felix test were excluded due to its established poor diagnostic accuracy and the lengthy time required to perform \[[@pntd.0006330.ref009],[@pntd.0006330.ref021]\]. Meta-analysis and meta-regression were performed on studies of commercially available POCTs with an extractable diagnostic accuracy 2 by 2 table.

Search strategy {#sec007}
---------------

After a preliminary search, ICT, dot-blot, and LAMP were searched for specifically. The search was conducted on articles cited in PubMed up to 2 February 2017 combining the search terms 'scrub typhus', 'immunochromatography', 'dot blot immunoassay', and 'loop mediated isothermal amplification' without any other restrictions (i.e., \"scrub typhus\" AND (rapid diagnosis OR immunochromatograph\* OR dot blot immunoassay OR loop mediated isothermal amplification). The titles and abstracts were screened and the full text of relevant articles were reviewed. Manual screening of the reference list of relevant articles was also performed.

Quality assessment {#sec008}
------------------

The quality of the studies was assessed with the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) \[[@pntd.0006330.ref022]\]. QUADAS-2 was used as a quality scoring system to determine the risk of bias and the applicability of the paper \[[@pntd.0006330.ref022]\]. It evaluates four main areas: 'patient selection', 'index test', 'reference standard', and 'flow and timing' \[[@pntd.0006330.ref022]\]. These are assessed by using seven 'signalling questions' (e.g., "was a case-control design avoided?") with 'yes', 'no', and 'unclear' answer \[[@pntd.0006330.ref022]\]. The answers to these 'signalling questions' were then used to judge whether the risk of bias is low and if there is low concern for the applicability of the research \[[@pntd.0006330.ref022]\]. If the response to the risk of bias and applicability questions were 'low risk' or 'low concern', the articles were given one point each. The articles were grouped based on their score into high (6--7 points), moderate (4--5 points), and low (0--3 points) quality categories.

Data extraction {#sec009}
---------------

Data was extracted primarily by one author (KS) and where the results were unclear a second author (SB) was consulted. The data was recorded on a form developed through an iterative process to ensure that all the required data could be collected for future reference. The parameters extracted include: citation information, methodology (i.e., study design, participant characteristics, index and reference test details), and the diagnostic accuracy results (including sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and if available, numbers required to construct a 2 by 2 contingency table.

Statistical data analysis and reporting {#sec010}
---------------------------------------

The extracted data were compiled into summary tables and analysed through narrative synthesis. Meta-analysis and meta-regression were performed on commercially available POCT diagnostic accuracy data, excluding studies with low quality (i.e. QUADAS-2 score of 3 or less). The ones in development stage/prototype were not included in the meta-analysis and meta-regression, but included in the narrative synthesis. If one study derived more than one 2 by 2 table, each table was extracted as separate data. However, if one study used more than one reference test cut-off titre, only data using one cut-off value above 1:3,200 were used to ensure accuracy \[[@pntd.0006330.ref012]\]. In performing the meta-regression, relevant signalling questions with 'unclear' as the answers were entered as 'no' to turn these into dichotomous variables. Statistical analysis was done with STATA/IC 14.0 (College Station, TX) using MIDAS and METANDI commands. In the meta-analyses, heterogeneity was assessed using the Chi-square statistic, higher values of the Chi-square (and hence low p-value) being consistent with heterogeneity. In the summary statistics of the resulting forest plot, overall sensitivity and specificity were estimated and reported alongside the 95% confidence interval. In addition, study specific estimates were provided in the same plot to visualize how the estimates from each of the studies deviate from the overall estimate. Most of the results was presented graphically. The data was analysed, summarised, and presented following the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement as much as possible \[[@pntd.0006330.ref023]\]. This review was registered in the International Prospective Register for Systematic Review (PROSPERO) with registration number CRD42017056727.

Results {#sec011}
=======

Search results {#sec012}
--------------

There were 133 articles in total identified through database searching and reference list screening ([Fig 1](#pntd.0006330.g001){ref-type="fig"}). After title and abstract screening and full text review, we included 31 relevant articles. There were six articles excluded after full text review. Since this study only focused on human diagnostics, one article using rabbit sera in its negative sera panel was excluded. One study involved DNA extraction, which is not applicable as a POCT in resource-limited settings. Four other papers were excluded due to language (not in English, n = 2) and study design (not experimental diagnostic accuracy studies, n = 2). There were 20 articles on ICTs, eight articles on dot-blot assays, four articles on LAMP assays, and one each on a passive hemagglutination assay, an IgM dot immunobinding assay, and a latex agglutination test. Four articles evaluated more than one type of diagnostic test. There were 11 studies that evaluated diagnostic tests still in development and 21 studies on prototype/commercial tests.

![PRISMA flow diagram.](pntd.0006330.g001){#pntd.0006330.g001}

Characteristics of the included studies {#sec013}
---------------------------------------

In total, there were 6,772 samples analysed. The samples were taken from 12 countries, with most studies recruiting in Thailand (n = 15, 48.4% of included studies), India (n = 5, 16.1%), Laos (n = 3, 9.7%), and Korea (n = 3, 9.7%). There was one study each (3.2%) conducted on samples from Sri Lanka, Nepal, Malaysia, Peru, Indonesia, United States of America, and Australia. There were five studies (16.1%) with unclear sample collection location. Ten (32.2%) studies collected paired samples (acute and convalescent phase), while 15 studies (48.4%) did not provide sufficient details on sample collection timing ([Table 1](#pntd.0006330.t001){ref-type="table"}).

10.1371/journal.pntd.0006330.t001

###### Summary of included studies.

![](pntd.0006330.t001){#pntd.0006330.t001g}

  First author                                       Year   Sample collection location       Index test assay type                          Reference test assay type                                                                QUADAS a 2 score
  -------------------------------------------------- ------ -------------------------------- ---------------------------------------------- ---------------------------------------------------------------------------------------- ------------------
  Anitharaj et al \[[@pntd.0006330.ref033]\]         2016   India                            ICT IgM                                        ELISA                                                                                    5
  Blacksell et al \[[@pntd.0006330.ref034]\]         2010   Laos                             ICT IgM                                        IFA                                                                                      6
  Blacksell et al \[[@pntd.0006330.ref028]\]         2010   Laos and Thailand                ICT IgM; ICT IgG, IgM                          IFA and/or PCR and/or culture                                                            5
  Blacksell et al \[[@pntd.0006330.ref019]\]         2012   Thailand                         ICT IgM; ICT IgG, IgM; LAMP                    STIC (cell culture isolation, PCR, IFA)                                                  6
  Cao et al \[[@pntd.0006330.ref025]\]               2007   China                            ICT IgG, IgM; ICT IgG; ICT IgM                 Unclear                                                                                  2
  Ching et al \[[@pntd.0006330.ref024]\]             2001   Unclear                          ICT IgG, IgM; ICT IgG; ICT IgM                 IFA                                                                                      2
  Chinprasatsak et al \[[@pntd.0006330.ref035]\]     2001   Thailand                         Dot-blot IgG, IgM                              IIP                                                                                      6
  Coleman et al \[[@pntd.0006330.ref036]\]           2002   Thailand                         Dot-blot IgG, dot-blot IgM, ICT IgG, ICT IgM   IIP                                                                                      7
  Huber et al \[[@pntd.0006330.ref037]\]             2012   Unclear                          LAMP                                           PCR                                                                                      2
  Kim et al \[[@pntd.0006330.ref038]\]               1993   Unclear                          Passive hemagglutination assay                 IFA                                                                                      3
  Kim et al \[[@pntd.0006330.ref039]\]               2013   Korea                            ICT IgG, IgM; dot-blot IgG                     Unclear                                                                                  2
  Kim et al \[[@pntd.0006330.ref040]\]               2016   Korea, Sri Lanka, India          ICT IgG, IgM                                   IFA                                                                                      3
  Kingston et al \[[@pntd.0006330.ref041]\]          2015   Thailand, Nepal                  ICT IgM PAb, Mab                               IFA                                                                                      6
  Koay et al \[[@pntd.0006330.ref042]\]              1995   Unclear                          IgM dot-immunobinding assay                    IIP                                                                                      3
  Lee et al \[[@pntd.0006330.ref027]\]               2014   Korea                            ICT IgG, IgM, IgA                              IFA                                                                                      4
  Paris et al \[[@pntd.0006330.ref043]\]             2008   Thailand, Laos                   LAMP                                           In vitro isolates, IFA, PCR, ICT IgG & IgM                                               3
  Paris et al \[[@pntd.0006330.ref020]\]             2011   Thailand                         ICT IgM, LAMP                                  STIC (Cell culture isolation, PCR, IFA)                                                  6
  Pradutkanchana et al \[[@pntd.0006330.ref044]\]    1997   Thailand                         Dot-blot IgG, IgM                              IFA                                                                                      4
  Prakash et al \[[@pntd.0006330.ref045]\]           2006   India                            Dot-blot IgG, IgM                              Dot EIA, ELISA, clinical response to antibiotics[^a^](#t001fn001){ref-type="table-fn"}   3
  Ramyasree et al \[[@pntd.0006330.ref046]\]         2015   Unclear                          ICT IgM                                        ELISA                                                                                    5
  Rodkvamtook et al \[[@pntd.0006330.ref047]\]       2015   Thailand                         Dot-blot IgG, IgM                              IFA                                                                                      5
  Silpasakorn et al \[[@pntd.0006330.ref048]\]       2012   Thailand                         ICT IgM, ICT IgG                               PCR & IFA                                                                                4
  Silpasakorn et al \[[@pntd.0006330.ref049]\]       2012   Thailand                         ICT IgG, IgM, IgA                              PCR & IFA                                                                                3
  Stephen et al \[[@pntd.0006330.ref050]\]           2015   India                            ICT IgG, IgM, IgA                              ELISA IgM, IgG                                                                           5
  Stephen et al \[[@pntd.0006330.ref051]\]           2016   India                            ICT IgG, ICT IgM                               IFA                                                                                      5
  Watt et al \[[@pntd.0006330.ref052]\]              1998   Thailand                         Dot-blot IgG, IgM                              IFA                                                                                      5
  Watthanaworawit et al \[[@pntd.0006330.ref029]\]   2015   Thailand                         ICT IgM; IgG, IgM, IgA                         PCR & IFA                                                                                5
  Weddle et al \[[@pntd.0006330.ref053]\]            1995   Malaysia, Peru, Indonesia, USA   Dot-blot immunoassay IgG, IgM                  IFA                                                                                      4
  Wilkinson et al \[[@pntd.0006330.ref054]\]         2003   Thailand, Australia              ICT IgG, ICT IgM                               Unclear                                                                                  2
  Wongchotigul et al \[[@pntd.0006330.ref055]\]      2005   Thailand                         Latex agglutination test                       IFA                                                                                      4
  Zhang et al \[[@pntd.0006330.ref026]\]             2011   China                            InBios ICT IgG, ICT IgM                        IgM and IgG antibodies detection (tests unclear) and PCR                                 4

^a^Doxycycline or chloramphenicol

Quality of articles {#sec014}
-------------------

There are 7, 14, and 10 articles with good, moderate, and low quality, respectively ([Table 1](#pntd.0006330.t001){ref-type="table"}). Two articles fulfilled all of the QUADAS-2 main criteria ([S1 Dataset](#pntd.0006330.s001){ref-type="supplementary-material"}). Most of the articles (n = 8, 25.8%) scored 5 points. Two articles (6.5%) scored full points for the risk of bias component (i.e. 4 points), although most of the articles scored only 1 point (n = 12, 38.7%). The majority of the articles scored 3 points in the applicability component (n = 22, 71.0%). There were 24.4% (n = 53/217) sub-questions with 'unclear' response. Among the 'unclear' response, most of those responses (n = 45, 84.9%) were observed in the index test and reference standard domain of the risk of bias assessment ([Fig 2](#pntd.0006330.g002){ref-type="fig"}). The main reason for this is that most of the articles did not mention explicitly whether they performed blinding during the conduct and interpretation of both the index test (n = 23, 74.2%) and reference test (n = 25, 80.6%) ([S2 Dataset](#pntd.0006330.s002){ref-type="supplementary-material"}). There were 20 studies (64.5%) with a case-control study design.

![QUADAS-2 finding per domain.](pntd.0006330.g002){#pntd.0006330.g002}

Performance of POCT {#sec015}
-------------------

### IgM ICT {#sec016}

There were five manufacturers of IgM ICT identified ([Table 2](#pntd.0006330.t002){ref-type="table"}), namely: AccessBio, InBios, PanBio, Standard Diagnostic (SD), and ImmuneMed. There were two studies (6.6%) that assessed in-house tests \[[@pntd.0006330.ref024],[@pntd.0006330.ref025]\]. The sensitivity ranged from 23.3% to 100.0%, and the specificity ranged from 73.0% to 100.0% ([Fig 3](#pntd.0006330.g003){ref-type="fig"}, results from Zhang et al, 2011 and Lee et al, 2014 were not plotted since only sensitivity values were presented \[[@pntd.0006330.ref026],[@pntd.0006330.ref027]\]). The accuracy across data points of the same manufacturers varied across the studies. The InBios IgM ICT tests reported \>80.0% sensitivity and \>90.0% specificity on average. The ImmuneMed IgM ICT demonstrated sensitivity of 99.0% and specificity of 98.0%, however, there was only one data point for this manufacturer. One of the studies reported sensitivity and specificity for the AccessBio ICT IgM of 97.0% and 93.0%, respectively. However, the other AccessBio studies did not demonstrate such a high degree of accuracy ([Fig 3](#pntd.0006330.g003){ref-type="fig"}).

![IgM ICT sensitivity and specificity range\*.](pntd.0006330.g003){#pntd.0006330.g003}

10.1371/journal.pntd.0006330.t002

###### Summary of ICT IgM.

![](pntd.0006330.t002){#pntd.0006330.t002g}

  Assay                                              Study                                        Year       Location of sample collection                                                                                                                                Sample collection timing                                                                                                          Reference test assay type                                                                           Reference assay positivity cut-off                               Sensitivity (%)/ specificity (%)
  -------------------------------------------------- -------------------------------------------- ---------- ------------------------------------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------- ---------------------------------------------------------------- ----------------------------------
  CareStart, AccessBio                               Blacksell et al \[[@pntd.0006330.ref028]\]   2010       Laos and Thailand                                                                                                                                            Acute phase                                                                                                                       IFA and/or PCR and/or culture                                                                       IFA: 4-fold rise in paired serum samples                         96.8/93.3
  Blacksell et al \[[@pntd.0006330.ref019]\]         2012                                         Thailand   Acute (median 5 days of fever, IQR 3 to 7 days) and convalescent phase                                                                                       STIC                                                                                                                              IFA: an admission IgM titre of 1:12,800, and/or a 4-fold rising IgM titre in paired serum samples   55.6/90.0                                                        
  Watthanaworawit et al \[[@pntd.0006330.ref029]\]   2015                                         Thailand   Acute (median 2 days of fever, IQR: 2--3 days) and convalescent phase (median interval to convalescent sample collection was 14 days, range: 11--30 days).   PCR & IFA                                                                                                                         ≥ 4-fold increase in IFA IgM titer, 1:25,600                                                        Acute samples: 23.3/81.4                                         
  Paired samples: 32.6/79.1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  ImmuneMed                                          Stephen et al \[[@pntd.0006330.ref051]\]     2016       India                                                                                                                                                        Acute phase with partly paired samples                                                                                            IFA                                                                                                 1:40                                                             87.0/94.6
  InBios                                             Zhang et al \[[@pntd.0006330.ref026]\]       2011       China                                                                                                                                                        Acute phase: 2 to 10 days after onset                                                                                             IgM and IgG antibodies detection (unclear) and PCR                                                  Unclear                                                          Sensitivity 93.9%
  Silpasakorn et al \[[@pntd.0006330.ref048]\]       2012                                         Thailand   Acute and convalescent phase                                                                                                                                 PCR & IFA                                                                                                                         IFA: IgM 1:400 or a 4-fold increase                                                                 90.2/85.5                                                        
  InBios prototype                                   Kingston et al \[[@pntd.0006330.ref041]\]    2015       Thailand, Nepal                                                                                                                                              Unclear                                                                                                                           IFA                                                                                                 1:400                                                            PAb: 52.0/97.0
  1:400                                              MAb: 52.0/96.0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  1:1,600                                            PAb: 82.0/98.0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  1:1,600                                            MAb: 82.0/96.0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  1:6,400                                            PAb: 92.0/95.0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  1:6,400                                            MAb: 92.0/94.0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  1:25,600                                           PAb: 100.0/94.0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  1:25,600                                           MAb: 100.0/93.0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  PanBio                                             Blacksell et al \[[@pntd.0006330.ref034]\]   2010       Laos                                                                                                                                                         Admission phase: median 6 days of fever (IQR = 5--10 days); median interval to convalescent sampling: 7 days (IQR = 5--10 days)   IFA                                                                                                 ≥ 1:400                                                          23.8/86.2
  4-fold increase in paired samples                  31.9/99.5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  Combination of the above                           34.7/99.7                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  Paris et al \[[@pntd.0006330.ref020]\]             2011                                         Thailand   Mostly paired samples. Median fever before admission = 5 days (IQR: 3--7)                                                                                    STIC                                                                                                                              IFA: an admission IgM titer ≥1:12,800 and/or a 4-fold increase                                      47.0/95.0                                                        
  Blacksell et al \[[@pntd.0006330.ref019]\]         2012                                         Thailand   Acute (median 5 days of fever, IQR 3 to 7 days) and convalescent phase                                                                                       STIC                                                                                                                              IFA: an admission IgM titer ≥1:12,800 and/or a 4-fold increase                                      46.3/95.1                                                        
  PanBio prototype                                   Wilkinson et al \[[@pntd.0006330.ref054]\]   2003       Thailand, Australia                                                                                                                                          Unclear                                                                                                                           Unclear                                                                                             Unclear                                                          95.8/86.0
  SD Bioline Tsutsugamushi                           Blacksell et al \[[@pntd.0006330.ref019]\]   2012       Thailand                                                                                                                                                     Acute (median 5 days of fever, IQR 3 to 7 days) and convalescent phase                                                            STIC                                                                                                IFA: an admission IgM titer ≥1:12,800 and/or a 4-fold increase   67.9/73.0
  Ramyasree et al \[[@pntd.0006330.ref046]\]         2015                                         India?     Unclear                                                                                                                                                      ELISA                                                                                                                             Unclear                                                                                             Agreement 97%                                                    
  In-house tests                                     Ching et al \[[@pntd.0006330.ref024]\]       2001       Unclear                                                                                                                                                      Unclear                                                                                                                           IFA                                                                                                 \>1:40                                                           74.0/99.0
  Cao et al \[[@pntd.0006330.ref025]\]               2007                                         China      Unclear                                                                                                                                                      Unclear                                                                                                                           Unclear                                                                                             81.2%/100.0                                                      

### Total antibody ICT {#sec017}

The ICTs with IgG, combination of IgG and IgM, and combination of IgG, IgM, and IgA as the detection target were grouped together under 'total antibody ICT' ([Table 3](#pntd.0006330.t003){ref-type="table"}). There were five manufacturers identified, namely: AccessBio, ImmuneMed, InBios, PanBio, and SD. The remaining studies (n = 3, 6.6%) assessed the diagnostic performance of in-house tests in development. The sensitivity and specificity ranged from 20.9% to 99.1% and 67.9% to 100.0%, respectively ([Fig 4](#pntd.0006330.g004){ref-type="fig"}, results from and Zhang et al, 2011 and Lee et al, 2014 were not plotted since only sensitivity values were presented \[[@pntd.0006330.ref026],[@pntd.0006330.ref027]\]). As in the case of IgM ICT, the accuracy across data points of total antibody ICT of the same manufacturer varies. The ImmuneMed total antibody ICT demonstrated \>95.0% specificity and \>80.0% sensitivity.

![Total antibody ICT sensitivity and specificity range\*.](pntd.0006330.g004){#pntd.0006330.g004}

10.1371/journal.pntd.0006330.t003

###### Summary table of total antibody ICT.

![](pntd.0006330.t003){#pntd.0006330.t003g}

  Assay                                                                                    Study                                                                                Year                                          Location of sample collection                                                                                                                                                  Sample collection timing                                                                                                                                  Reference test assay type                                                                           Reference assay positivity cut-off                              Sensitivity (%)/ specificity (%)
  ---------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------ --------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------- --------------------------------------------------------------- ----------------------------------
  CareStart, AccessBio                                                                     Blacksell et al[^a^](#t003fn001){ref-type="table-fn"} \[[@pntd.0006330.ref028]\]     2010                                          Laos and Thailand                                                                                                                                                              Acute phase                                                                                                                                               IFA and/or PCR and/or culture                                                                       IFA: 4-fold rise in paired serum samples                        97.6/71.4
  Blacksell et al[^a^](#t003fn001){ref-type="table-fn"} \[[@pntd.0006330.ref019]\]         2012                                                                                 Thailand                                      Acute (median 5 days of fever, IQR 3 to 7 days) and convalescent phase                                                                                                         STIC                                                                                                                                                      IFA: an admission IgM titre of 1:12,800, and/or a 4-fold rising IgM titre in paired serum samples   60.5/67.9                                                       
  ImmuneMed                                                                                Kim et al[^a^](#t003fn001){ref-type="table-fn"} \[[@pntd.0006330.ref039]\]           2013                                          Korea                                                                                                                                                                          Unclear                                                                                                                                                   Unclear                                                                                             Unclear                                                         99.1/98.9
  Kim et al[^b^](#t003fn002){ref-type="table-fn"} \[[@pntd.0006330.ref040]\]               2016                                                                                 Korea[^d^](#t003fn004){ref-type="table-fn"}   Unclear                                                                                                                                                                        IFA IgM                                                                                                                                                   1:10                                                                                                98.6/98.2                                                       
  IFA IgG                                                                                  1:40                                                                                 97.1/97.7                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  Korea[^e^](#t003fn005){ref-type="table-fn"}                                              Unclear                                                                              IFA IgM                                       1:10                                                                                                                                                                           98.6/97.6                                                                                                                                                                                                                                                                                                                     
  IFA IgG                                                                                  1:40                                                                                 97.1/97.0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  Sri Lanka                                                                                Unclear                                                                              IFA                                           Unclear                                                                                                                                                                        92.1/96.1                                                                                                                                                                                                                                                                                                                     
  India                                                                                    Unclear                                                                              IFA IgM                                       1:10                                                                                                                                                                           Sensitivity 86.0%                                                                                                                                                                                                                                                                                                             
  IFA IgG                                                                                  1:40                                                                                 Sensitivity 92.0%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Stephen et al[^b^](#t003fn002){ref-type="table-fn"} \[[@pntd.0006330.ref051]\]           2016                                                                                 India                                         Acute and convalescent phase                                                                                                                                                   IFA                                                                                                                                                       1:80                                                                                                77.3/86.4                                                       
  InBios                                                                                   Zhang et al[^b^](#t003fn002){ref-type="table-fn"} \[[@pntd.0006330.ref026]\]         2011                                          China                                                                                                                                                                          Acute phase: 2 to 10 days after onset of illness                                                                                                          IgM and IgG antibodies detection (unclear) and PCR                                                  Unclear                                                         Sensitivity 90.9%
  Silpasakorn et al[^c^](#t003fn003){ref-type="table-fn"} \[[@pntd.0006330.ref048]\]       2012                                                                                 Thailand                                      Acute and convalescent phase                                                                                                                                                   PCR & IFA                                                                                                                                                 IFA: IgG 1:800 or a 4-fold increase                                                                 66.7%/98.4                                                      
  PanBio                                                                                   Coleman et al[^b^](#t003fn002){ref-type="table-fn"} \[[@pntd.0006330.ref036]\]       2002                                          Thailand                                                                                                                                                                       Acute phase                                                                                                                                               IIP                                                                                                 1:400                                                           90.4/95.8
  Panbio prototype                                                                         Wilkinson et al[^b^](#t003fn002){ref-type="table-fn"} \[[@pntd.0006330.ref054]\]     2003                                          Thailand, Australia                                                                                                                                                            Unclear                                                                                                                                                   Unclear                                                                                             Unclear                                                         96.1/93.0
  SD Bioline Tsutsugamushi                                                                 Silpasakorn et al[^c^](#t003fn003){ref-type="table-fn"} \[[@pntd.0006330.ref049]\]   2012                                          Thailand                                                                                                                                                                       Acute phase: median 6 days of fever (range 1--47 days); median interval between obtaining admission and convalescence phase: 13 days (range 3--32 days)   PCR & IFA                                                                                           IFA: IgM or IgG IFA assay titre \> 1:400 or a 4-fold increase   66.7/98.4
  Lee et al[^c^](#t003fn003){ref-type="table-fn"} \[[@pntd.0006330.ref027]\]               2014                                                                                 Korea                                         Unclear                                                                                                                                                                        IFA                                                                                                                                                       4-fold rise or single titre ≥ 1:160                                                                 Sensitivity 72.6%                                               
  Stephen et al[^c^](#t003fn003){ref-type="table-fn"} \[[@pntd.0006330.ref050]\]           2015                                                                                 India                                         Acute and convalescence phase                                                                                                                                                  ELISA IgM                                                                                                                                                 Unclear                                                                                             91.7/90.5                                                       
  ELISA IgG                                                                                Unclear                                                                              85.7/100.0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Watthanaworawit et al[^c^](#t003fn003){ref-type="table-fn"} \[[@pntd.0006330.ref029]\]   2015                                                                                 Thailand                                      Median fever = 2 days (IQR: 2--3 days), and the median interval between obtaining initial acute-phase specimens and convalescent specimens was 14 days (range: 11--30 days).   PCR & IFA                                                                                                                                                 ≥ 4-fold increase in IFA IgM titre, 1:25,600                                                        Acute samples: 20.9/74.4                                        
  Paired samples: 76.7/76.7                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  In-house tests                                                                           Ching et al[^a^](#t003fn001){ref-type="table-fn"} \[[@pntd.0006330.ref024]\]         2001                                          Unclear                                                                                                                                                                        Unclear                                                                                                                                                   IFA                                                                                                 \>1:40                                                          IgG: 86.0/97.0
  IgG, IgM: 89.0/97.0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Cao et al[^a^](#t003fn001){ref-type="table-fn"} \[[@pntd.0006330.ref025]\]               2007                                                                                 China                                         Unclear                                                                                                                                                                        Unclear                                                                                                                                                   Unclear                                                                                             IgG: 94.6/98.9                                                  
  IgG, IgM: 98.2/98.1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

^a^Total antibody: IgG & IgM

^b^IgG

^c^IgG, IgM, IgA

^d^Healthy control sera

^e^Diseases non-scrub typhus control sera

### Dot-blot {#sec018}

Aside from the in-house tests assessed by four studies, there were two dot-blot assay manufacturers, namely Integrated Diagnostics and PanBio. The range was 59.6% to 100.0% and 83.0% to 98.7% for sensitivity and specificity, respectively ([Table 4](#pntd.0006330.t004){ref-type="table"}).

10.1371/journal.pntd.0006330.t004

###### Summary of articles on dot-blot, LAMP and other assays.

![](pntd.0006330.t004){#pntd.0006330.t004g}

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Assay type                                                                  Assay                                                            Study                                             Year                                                                                    Location of sample collection                                            Sample collection timing                                                                                                                        Reference test assay type                                                                      Reference assay positivity cut-off                                  Sensitivity (%)/ specificity (%)
  --------------------------------------------------------------------------- ---------------------------------------------------------------- ------------------------------------------------- --------------------------------------------------------------------------------------- ------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------- ------------------------------------------------------------------- ----------------------------------
  Immunoblot                                                                  Dip-S-Ticks, Integrated Diagnostics                              Pradutkanchana et al \[[@pntd.0006330.ref044]\]   1997                                                                                    Thailand                                                                 Unclear                                                                                                                                         IFA                                                                                            ≥1:400 or a 4-fold or greater rise in IFA titre to at least 1:200   94.0/98.7

  Chinprasatsak et al \[[@pntd.0006330.ref035]\]                              2001                                                             Thailand                                          Acute and convalescent phase                                                            IIP                                                                      "Four-fold or greater rise in IIP titre to at least 1:200, or a single IgM antibody titre of ≥ 1:400 and/or IgG antibody titre of ≥ 1:1,600."   86.7/94.3                                                                                                                                                          

  Coleman et al \[[@pntd.0006330.ref036]\]                                    2002                                                             Thailand                                          Acute phase                                                                             IIP                                                                      1:400                                                                                                                                           IgM: 60.3/97.4\                                                                                                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  IgG: 59.6/95.3\                                                                                                                                                    

  Rickettsia Screen, PanBio                                                   Prakash et al \[[@pntd.0006330.ref045]\]                         2006                                              India                                                                                   Acute phase                                                              Dot EIA, ELISA, clinical response to antibiotics[\*](#t004fn001){ref-type="table-fn"}                                                           ELISA: ≥16 PanBio units                                                                        100.0/93.5                                                          

  In-house                                                                    Weddle et al \[[@pntd.0006330.ref053]\]                          1995                                              Malaysia, Peru, Indonesia, USA                                                          Acute phase, unclear for negative panel                                  IFA                                                                                                                                             \<1:64, \>1:128, if in between depends on clinical condition                                   90.0/83.0                                                           

  Watt et al \[[@pntd.0006330.ref052]\]                                       1998                                                             Thailand                                          High-antigen dipstick: median = 4 days of fever (range = 2--14)                         IFA                                                                      IgG 1:1600 and/or IgM 1:400                                                                                                                     67.0/98.0                                                                                                                                                          

                                                                              Low-antigen dipstick: median = 4 days of fever (range = 2--30)   100.0/98.0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Kim et al[\^](#t004fn002){ref-type="table-fn"} \[[@pntd.0006330.ref039]\]   2013                                                             Korea                                             Unclear                                                                                 Unclear                                                                  Unclear                                                                                                                                         97.7/98.6                                                                                                                                                          

  Rodkvamtook et al \[[@pntd.0006330.ref047]\]                                2015                                                             Thailand                                          Acute phase: fever no more than 2 weeks;                                                IFA                                                                      1:400 or 4-fold increase for IgG & IgM                                                                                                          98.5/96.3                                                                                                                                                          

                                                                                                                                                                                                 Paired sample. Convalescent phase: collected after 3--14 days after the acute sample.   98.3/97.0                                                                                                                                                                                                                                                                                                                                                                                   

  LAMP                                                                        Loopamp kit, Eiken Chemical LAMP                                 Paris et al \[[@pntd.0006330.ref043]\]            2008                                                                                    Thailand, Laos                                                           Acute phase for positive panel                                                                                                                  IFA                                                                                            4-fold rise or single titre ≥ 1:160\                                Sensitivity 72.6%

  Paris et al \[[@pntd.0006330.ref020]\]                                      2011                                                             Thailand                                          Mostly paired samples. Median fever before admission = 5 days (IQR: 3--7)               In vitro isolates, IFA, PCR, ICT IgG & IgM                               1:400 and four-fold rise of paired serum for IgM IFA\                                                                                           100.0/100.0                                                                                                                                                        

  In-house LAMP                                                               Huber et al \[[@pntd.0006330.ref037]\]                           2012                                              Not stated                                                                              Not stated in detail                                                     PCR                                                                                                                                             N/A                                                                                            90.0/80.0                                                           

  Combined Panbio ICT IgM and in-house LAMP                                   Blacksell et al \[[@pntd.0006330.ref019]\]                       2012                                              Thailand                                                                                Acute (median 5 days of fever, IQR 3 to 7 days) and convalescent phase   STIC (cell culture isolation, PCR, IFA)                                                                                                         IFA: an admission IgM titre of 1:12,800, and/or a 4-fold rising IgM titre in paired samples\   66.7/90.6                                                           

  Combined SD ICT IgM and in-house LAMP                                       Blacksell et al \[[@pntd.0006330.ref019]\]                       2012                                              Thailand                                                                                Acute (median 5 days of fever, IQR 3 to 7 days) and convalescent phase   STIC (cell culture isolation, PCR, IFA)                                                                                                         IFA: an admission IgM titre of 1:12,800, and/or a 4-fold rising IgM titre in paired samples\   77.2/68.2                                                           

  Combined AccessBio ICT IgG, IgM and in-house LAMP                           Blacksell et al \[[@pntd.0006330.ref019]\]                       2012                                              Thailand                                                                                Acute (median 5 days of fever, IQR 3 to 7 days) and convalescent phase   STIC (cell culture isolation, PCR, IFA)                                                                                                         IFA: an admission IgM titre of 1:12,800, and/or a 4-fold rising IgM titre in paired samples\   68.5/84.9                                                           

  Combined AccessBio ICT IgM and in-house LAMP                                Blacksell et al \[[@pntd.0006330.ref019]\]                       2012                                              Thailand                                                                                Acute (median 5 days of fever, IQR 3 to 7 days) and convalescent phase   STIC (cell culture isolation, PCR, IFA)                                                                                                         IFA: an admission IgM titre of 1:12,800, and/or a 4-fold rising IgM titre in paired samples\   71.6/63.2                                                           

  Others                                                                      Passive hemagglutination assay                                   Kim et al \[[@pntd.0006330.ref038]\]              1993                                                                                    Unclear                                                                  Unclear                                                                                                                                         IFA                                                                                            Seroconversion or 4-fold rise\                                      99.0/98.9

  IgM dot-immunobinding assay                                                 Koay et al \[[@pntd.0006330.ref042]\]                            1995                                              Unclear                                                                                 Unclear                                                                  IIP                                                                                                                                             1:50\                                                                                          90.4/81.4                                                           

  Latex agglutination assay                                                   Wongchotigul et al \[[@pntd.0006330.ref055]\]                    2005                                              Thailand                                                                                Unclear                                                                  IFA                                                                                                                                             1:400\                                                                                         89.1/98.2                                                           
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Doxycycline or chloramphenicol

\^IgG only

### LAMP {#sec019}

The Loopamp LAMP kit (Eiken Chemical, Japan) was assessed in two studies ([Table 4](#pntd.0006330.t004){ref-type="table"}). The other two studies evaluated in-house tests. The sensitivity ranged from 66.7% to 100.0% and specificity ranged from 63.2% to 100.0%.

### Other methods {#sec020}

There was one study each on a passive hemagglutination assay, an IgM dot-immunobinding assay, and a latex agglutination assay ([Table 4](#pntd.0006330.t004){ref-type="table"}). These tests were all in the development phase.

Meta-analysis results {#sec021}
---------------------

There were 11 data points extracted from four studies included in the meta-analysis ([Fig 5](#pntd.0006330.g005){ref-type="fig"}). In the resulting forest plot ([Fig 5](#pntd.0006330.g005){ref-type="fig"}), the top three data were extracted from studies assessing total antibody ICT (Blacksell et al, 2010 and Watthanaworawit et al, 2015) \[[@pntd.0006330.ref028],[@pntd.0006330.ref029]\]. The rest of the 2 by 2 table data were extracted from studies assessing IgM ICT diagnostic performance. The pooled sensitivity and specificity were 66.0% (95% CI 0.37--0.86) and 92.0% (95% CI 0.83--0.97), respectively. The overall Chi-square heterogeneity statistics showed significant heterogeneity (p \< 0.001). There is a high degree of heterogeneity present (I^2^ value = 97.48%, 95% CI 96.71--98.24 for sensitivity and I^2^ value = 98.17%, 95% CI 97.67--98.67 for specificity). Meta-regression on several covariates was performed in an attempt to explain this heterogeneity. Significant heterogeneity was observed for total number of samples (p = 0.01), study design (whether using case-control design or not, p = 0.01), blinding during index test interpretation (p = 0.02), and QUADAS-2 score (p = 0.01). No significant heterogeneity was observed for the blinding during reference test interpretation (p = 0.21) and antibody target detection of the tests (p = 0.22). All of these studies used IFA as their reference standard, except Blacksell et al, 2010 which used IFA with the addition of PCR and culture \[[@pntd.0006330.ref028]\]. None of the meta-analysed studies used an IFA cut off lower than 1:400 as the reference comparator.

![Forest plot of sensitivity and specificity of current commercially available POCT.](pntd.0006330.g005){#pntd.0006330.g005}

Discussion {#sec022}
==========

There were 31 relevant articles included in this review. Almost half of the included articles were of moderate quality. The meta-analysis showed moderately low pooled sensitivity and good specificity of the current commercially available scrub typhus POCT. However, the studies were heterogeneous with the I^2^ value indicating a high degree of heterogeneity. Hence, the pooled sensitivity and specificity value needs to be interpreted with caution.

The systematic review and meta-analysis highlighted the methodological and clinical heterogeneity across scrub typhus POCT diagnostic accuracy studies. These differences made it difficult to pool results and compare studies. Meta-regression for other covariates of interest (e.g. sample collection timing) could not be performed because of limited information presented in the original articles.

Almost a quarter of the responses gathered in the main seven questions on QUADAS-2 quality assessment were 'unclear'. Although we did not assess the quality of reporting in this review, this finding indicates that the quality of reporting in the included studies is still arguably poor. Poorly conducted and controlled diagnostic accuracy studies are a waste of time, resources, and effort; moreover, if research is not accurately reported, it can hinder critical appraisal, replication, and meta-analysis of studies \[[@pntd.0006330.ref030]\]. The launch of reporting guidelines such as Standards for Reporting Diagnostic Accuracy (STARD) and PRISMA is a starting point in improving the quality of reporting, although they are not applied as much as they should be \[[@pntd.0006330.ref030],[@pntd.0006330.ref031]\]. Besides adhering to reporting guidelines, regulations should be adapted to incentivise better and more complete reporting \[[@pntd.0006330.ref031]\]. Creating a reporting infrastructure and building the capability of both authors and reviewers are also necessary to encourage better reporting \[[@pntd.0006330.ref031]\].

Approximately two thirds of the included studies used case-control design. Compared with studies that recruit patients consecutively, case-control study design (evaluating index test in separate diseased population and control group) overestimates diagnostic performance \[[@pntd.0006330.ref032]\]. Therefore, the results presented need to be interpreted with caution.

Aside from LAMP assay, all of the other POCTs reviewed here relied on antibody detection. Serological diagnosis is problematic in several ways. First, the primary serum collection may not contain sufficient antibodies since it takes time for antibodies to increase to a detectable level creating a "false negative" result. Second, in endemic populations with significant background immunity, an appropriate cut-off needs to be established to ensure accurate diagnosis otherwise there is the possibility of "false positives". Furthermore the issues regarding the selection of IgM as opposed to whole antibody is very much dependent on the situation. Conventional thought is that whole antibodies may give higher number of "false positive" results in endemic situations due to the presence of residual IgG from previous scrub typhus infections as was the case with the AccessBio ICTs tested in Thailand and Laos \[[@pntd.0006330.ref019],[@pntd.0006330.ref028]\]. These shortcomings of serology highlight the need to develop alternative diagnostic strategies.

Although being pooled from heterogeneous studies, the cumulative specificity confidence interval was above 80.0%. This indicates that commercially available ICTs have value in "ruling in" for the diagnosis of scrub typhus. However, it is difficult to draw conclusions with confidence based on the currently available evidence given the high degree of heterogeneity amongst the studies.

Another important consideration when performing a diagnostic accuracy study is the choice of reference comparator. Often the IFA, the serological "gold standard", is selected. However, this test is far from perfect. IFA result interpretation is subjective and there remains a lack of consensus on the optimum positivity cut-off. A cut-off is often adopted without sufficient local evidence, potentially resulting in incorrect diagnostic accuracy measures for the diagnostic under test \[[@pntd.0006330.ref015]\]. To evaluate the true accuracy of IFA, Bayesian latent class models (LCM) have been used. The models showed that the IFA IgM has sensitivity and specificity of 70.0% and 83.8%, respectively; therefore suggesting it to be unfit as a reference standard \[[@pntd.0006330.ref012]\]. An alternative reference comparator is the composite Scrub Typhus Infection Criteria (STIC), which have been proposed as a more robust method to diagnose scrub typhus with more confidence, by including a panel of parameters with high specificity \[[@pntd.0006330.ref020]\]. The panel includes: (i) isolation of *O*. *tsutsugamushi*, (ii) at least two positive out of the three PCR assays targeting the 56kDa, 47kDa, and groEL genes, (iii) admission IFA IgM titre of ≥1:12,800, (iv) 4-fold rise in IgM titre from paired samples \[[@pntd.0006330.ref012],[@pntd.0006330.ref019],[@pntd.0006330.ref020]\]. At least one of these criteria needs to be fulfilled for a positive scrub typhus diagnosis. However the Bayesian LCM also showed that STIC's sensitivity and specificity are less than optimal for a reference test (90.5% and 82.5%, respectively).

This study has several limitations. First, the search was performed in one database, and in English only which might have resulted in non-inclusion of relevant articles. Second, the article inclusion and quality assessment were completed primarily by one person, though we attempted to decrease the risk of bias by routine discussion of contentious studies amongst the authors. Third, several studies did not present all of the parameters that we wished to extract, hence limiting the meta-analysis, as we could not include all relevant papers due to the limited information presented in the papers.

In reality, there is only a small number of scrub typhus POCTs that are commercially available. The Panbio POCTs are no longer available and therefore the market is dominated by a few companies including InBios, Standard Diagnostics and AccessBio. Selecting the most appropriate POCT is very much dependant on a few key factors such as availability of product locally, the price and the shelflife. In this study we have not examined these local practical aspects that should be considered when selecting POCTs.

In the absence of robust POCTs, the presence of an eschar can be a valuable clinical sign strongly suggesting a diagnosis of scrub typhus. Although its reported presence is very variable, it is still regarded as pathognomonic. An eschar may go unnoticed by the patient since it is painless, often does not itch, can be small, and looks similar to post trauma scab. In addition, it may be located in a concealed area, such as the perineum or under the breasts. This emphasises the importance of performing a thorough physical examination.

Treating patients empirically based on the pathogen pattern in an area is common practice, but bears the risk of unnecessary or inappropriate treatment (with the attendant risks of side effects) and promotion of antimicrobial resistance. POCTs can play an important role in reducing the number of patients treated empirically and increasing the proportion of patients treated appropriately.

There is an urgent need to develop an affordable and accurate POCT. However, if POCTs still rely on serological measures only, they might not be able to provide diagnosis in time to inform treatment. Future research should also be directed towards developing new antigen-based tests to improve diagnostic accuracy in the early period of disease.
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